Vaxcyte Inc logo

PCVX - Vaxcyte Inc Share Price

$21.48 -0.0  -0.1%

Last Trade - 18/06/21

Mid Cap
Market Cap £799.2m
Enterprise Value £566.7m
Revenue £n/a
Position in Universe 2814th / 6927
Unlock PCVX Revenue
Relative Strength (%)
1m +10.4%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -63.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 1.00
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, VaxcyteInc revenues was not reported. Net loss decreased 22% to$21.2M. Lower net loss reflects Research and development -Balancing val decrease of 31% to $16.6M (expense), ForeignExchange Gain/LossNon-Business increase from $3K (expense)to $1.9M (income), Interest expense decrease from $7K(expense) to $0K. Basic Earnings per Share excludingExtraordinary Items increased from -$0.56 to -$0.41.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


PCVX Revenue Unlock PCVX Revenue

Net Income

PCVX Net Income Unlock PCVX Revenue

Normalised EPS

PCVX Normalised EPS Unlock PCVX Revenue

PE Ratio Range

PCVX PE Ratio Range Unlock PCVX Revenue

Dividend Yield Range

PCVX Dividend Yield Range Unlock PCVX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
PCVX EPS Forecasts Unlock PCVX Revenue
Profile Summary

Vaxcyte Inc. is a vaccine company. The Company is focused on developing vaccines designed to prevent or treat common and deadly infectious diseases worldwide. Its cell-free protein synthesis platform enables it to design and produce protein carriers and antigens. Its pipeline includes pneumococcal conjugate vaccine (PCV) candidates. Its lead vaccine candidate is VAX-24, a 24-valent investigational PCV. Its pipeline also includes VAX-XP, VAX-A1 and VAX-PG. The Company's second PCV, VAX-XP, uses its modular platform and builds on the technical proof of concept established by VAX-24. VAX-A1 is a conjugate vaccine being developed for group A strep infections. VAX-PG is being developed as a protein vaccine for the treatment of periodontitis.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
No. of Shareholders: 28
No. of Employees: 58
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 51,378,730
Free Float (0.0%)
Eligible for
PCVX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for PCVX
Upcoming Events for PCVX
Tuesday 10th August, 2021 Estimate
Q2 2021 Vaxcyte Inc Earnings Release
Wednesday 10th November, 2021 Estimate
Q3 2021 Vaxcyte Inc Earnings Release
Frequently Asked Questions for Vaxcyte Inc
What is the Vaxcyte Inc share price?

As of 18/06/21, shares in Vaxcyte Inc are trading at $21.48, giving the company a market capitalisation of £799.2m. This share price information is delayed by 15 minutes.

How has the Vaxcyte Inc share price performed this year?

Shares in Vaxcyte Inc are currently trading at $21.48 and the price has moved by -36.95% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Vaxcyte Inc price has moved by -53.74% over the past year.

What are the analyst and broker recommendations for Vaxcyte Inc?

There are no analysts currently covering Vaxcyte Inc.

When will Vaxcyte Inc next release its financial results?

Vaxcyte Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Vaxcyte Inc dividend yield?

Vaxcyte Inc does not currently pay a dividend.

Does Vaxcyte Inc pay a dividend?

Vaxcyte Inc does not currently pay a dividend.

When does Vaxcyte Inc next pay dividends?

Vaxcyte Inc does not currently pay a dividend.

How do I buy Vaxcyte Inc shares?

To buy shares in Vaxcyte Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Vaxcyte Inc?

Shares in Vaxcyte Inc are currently trading at $21.48, giving the company a market capitalisation of £799.2m.

Where are Vaxcyte Inc shares listed? Where are Vaxcyte Inc shares listed?

Here are the trading details for Vaxcyte Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: PCVX
What kind of share is Vaxcyte Inc?

Based on an overall assessment of its quality, value and momentum, Vaxcyte Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Vaxcyte Inc share price forecast 2021?

Shares in Vaxcyte Inc are currently priced at $21.48. At that level they are trading at 0.125% discount to the analyst consensus target price of 0.00.

Analysts covering Vaxcyte Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.25 for the next financial year.

How can I tell whether the Vaxcyte Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vaxcyte Inc. Over the past six months, the relative strength of its shares against the market has been -38.38%. At the current price of $21.48, shares in Vaxcyte Inc are trading at -27.74% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Vaxcyte Inc PE Ratio?

We were not able to find PE ratio data for Vaxcyte Inc.

Who are the key directors of Vaxcyte Inc?

Vaxcyte Inc's management team is headed by:

Grant Pickering - CEO
Jeff Fairman - CFD
Kurt Von Emster - CHM
Peter Hirth - DRC
Patrick Heron - DRC
Halley Gilbert - DRC
Robert Hopfner - DRC
Heath Lukatch - DRC
Jim Wassil - COO
Andrew Guggenhime - PRE
Jane Wright-Mitchell - CCO
Paul Sauer - SVP
Who are the major shareholders of Vaxcyte Inc?

Here are the top five shareholders of Vaxcyte Inc based on the size of their shareholding:

Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 14.62% (7.51m shares)
TPG Capital, L.P. Private Equity
Percentage owned: 8.87% (4.56m shares)
Janus Henderson Investors Investment Advisor/Hedge Fund
Percentage owned: 8.23% (4.23m shares)
Abingworth Management Limited Venture Capital
Percentage owned: 8.11% (4.17m shares)
RA Capital Management, LP Hedge Fund
Percentage owned: 7.52% (3.87m shares)
Similar to PCVX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.